NAV

Tymazoline

Identification

Name
Tymazoline
Accession Number
DB08803
Description

Tymazoline is a nasal preparation.

Type
Small Molecule
Groups
Experimental
Structure
Thumb
3D
Similar Structures
Weight
Average: 232.3214
Monoisotopic: 232.157563272
Chemical Formula
C14H20N2O
Synonyms
  • Tymazoline

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

For the treatment of Inflammation of the lining of the nose and paranasal sinuses and allergic inflammation of nasopharyngeal.

Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Tymazoline is a drug with antihistaminic and sympathomimetic properties. It locally reduces swelling, inflammation and mucosal secretions of the nasal passages.

Mechanism of action

Thymazen causes vasoconstriction of the nasal mucosa, reducing congestion and thus the swelling of the mucosa. Also reduces the secretions from the nose. Thymazen acts on alpha-adrenergic receptors, which reduces local inflammation of the nasal mucosa especially if their cause is an allergy.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

A large overdose or accidental oral intake, especially in children, may cause excessive sedation with drowsiness, reduced body temperature, heart rate relief and fluctuations in blood pressure and collapse.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
OxymetazolineThe absorption of Tymazoline can be decreased when combined with Oxymetazoline.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Thymazen

Categories

ATC Codes
R01AA13 — Tymazoline
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aromatic monoterpenoids. These are monoterpenoids containing at least one aromatic ring.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Aromatic monoterpenoids
Alternative Parents
Monocyclic monoterpenoids / Phenylpropanes / Cumenes / Phenoxy compounds / Phenol ethers / Toluenes / Alkyl aryl ethers / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds
show 5 more
Substituents
2-imidazoline / Alkyl aryl ether / Amidine / Aromatic heteromonocyclic compound / Aromatic monoterpenoid / Azacycle / Benzenoid / Carboximidamide / Carboxylic acid amidine / Cumene
show 18 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
U993RH5585
CAS number
24243-97-8
InChI Key
QRORCRWSRPKEHR-UHFFFAOYSA-N
InChI
InChI=1S/C14H20N2O/c1-10(2)12-5-4-11(3)8-13(12)17-9-14-15-6-7-16-14/h4-5,8,10H,6-7,9H2,1-3H3,(H,15,16)
IUPAC Name
2-[5-methyl-2-(propan-2-yl)phenoxymethyl]-4,5-dihydro-1H-imidazole
SMILES
CC(C)C1=C(OCC2=NCCN2)C=C(C)C=C1

References

General References
  1. Levrier J, Molon-Noblot S, Duval D, Lloyd KG: A new ex vivo method for the study of nasal drops on ciliary function. Fundam Clin Pharmacol. 1989;3(5):471-82. [PubMed:2481638]
  2. Lorino AM, Lofaso F, Drogou I, Abi-Nader F, Dahan E, Coste A, Lorino H: Effects of different mechanical treatments on nasal resistance assessed by rhinometry. Chest. 1998 Jul;114(1):166-70. [PubMed:9674465]
Human Metabolome Database
HMDB0015693
KEGG Drug
D07373
PubChem Compound
34154
PubChem Substance
99445273
ChemSpider
31478
ChEBI
134947
ChEMBL
CHEMBL2106467
ZINC
ZINC000000002232
PharmGKB
PA165958422
Wikipedia
Tymazoline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.118 mg/mLALOGPS
logP3.2ALOGPS
logP2.64ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)7.66ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area33.62 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.54 m3·mol-1ChemAxon
Polarizability27.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9947
Blood Brain Barrier-0.572
Caco-2 permeable-0.5359
P-glycoprotein substrateSubstrate0.7787
P-glycoprotein inhibitor INon-inhibitor0.8564
P-glycoprotein inhibitor IINon-inhibitor0.588
Renal organic cation transporterInhibitor0.6599
CYP450 2C9 substrateNon-substrate0.7725
CYP450 2D6 substrateNon-substrate0.5833
CYP450 3A4 substrateNon-substrate0.5478
CYP450 1A2 substrateInhibitor0.653
CYP450 2C9 inhibitorNon-inhibitor0.8779
CYP450 2D6 inhibitorInhibitor0.8674
CYP450 2C19 inhibitorNon-inhibitor0.8289
CYP450 3A4 inhibitorNon-inhibitor0.8562
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6477
Ames testNon AMES toxic0.78
CarcinogenicityNon-carcinogens0.9076
BiodegradationNot ready biodegradable0.9959
Rat acute toxicity3.2336 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5936
hERG inhibition (predictor II)Non-inhibitor0.6603
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 15, 2010 16:48 / Updated on June 12, 2020 16:52